Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 29, 2014

Primary Completion Date

August 12, 2015

Study Completion Date

August 12, 2015

Conditions
HER-2 Positive Gastric CancerGastrooesophageal CancerEsophageal Cancer
Interventions
DRUG

Afatinib

Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.

DRUG

Paclitaxel

On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Columbia University

OTHER

NCT02274012 - Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | Biotech Hunter | Biotech Hunter